Company

AnnJi Pharmaceutical Clinical trial filings

AnnJi Advances AJ201 into Pivotal Phase 3 ROMA‑KD Trial – The Only Investigational Therapy for SBMA in Late‑Stage Development Worldwide

AnnJi Pharmaceutical Co., Ltd. (TPEx: 7754), a clinical‑stage drug development company focused on innovative small molecules, announced that it is proceeding with the U.S. portion of its pivotal Phase 3…

October 5, 2026

Asymchem’s Tianjin Macromolecule Site Passes First FDA Pre‑Approval Inspection – EIR Issued for Commercial API Facility

October 4, 2026

Pfizer’s Oral Ritlecitinib Meets Primary Endpoints in Phase III Nonsegmental Vitiligo Trials – Largest‑Ever Oral Systemic Program Clears Path for Global Filings

October 3, 2026

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.

Lir Therapeutics VectorBuilder

VectorBuilder and Lir Therapeutics Forge AI Collaboration to Optimize AAV Capsids for Clinical Translation

August 20, 2026

Ascentage Pharma Finanical Reports

Ascentage Pharma 1H 2026: Revenue Jumps 29% to RMB 302 Million as Olverembatinib and Lisaftoclax Power Commercial Growth

August 26, 2026

Finanical Reports Hengrui Pharmaceuticals

Jiangsu Hengrui 1H 2026: Innovative Drug Sales Jump 16.4% to RMB 8.8 Billion, Offset Generic Drag as R&D Spending Climbs 19%